On October 31, 2022 Reata Pharmaceuticals, Inc. (Nasdaq: RETA) ("Reata," the "Company," "our," "us," or "we"), a clinical-stage biopharmaceutical company, reported that it will report financial results for the third quarter ended September 30, 2022, and provide an update on the Company’s business operations and clinical development programs on November 8, 2022, before the U.S. financial markets open (Press release, Reata Pharmaceuticals, OCT 31, 2022, View Sourcenews/news-details/2022/Reata-Pharmaceuticals-Inc.-to-Report-Third-Quarter-2022-Financial-Results-and-to-Provide-an-Update-on-Clinical-Development-Programs-on-November-8-2022/default.aspx" target="_blank" title="View Sourcenews/news-details/2022/Reata-Pharmaceuticals-Inc.-to-Report-Third-Quarter-2022-Financial-Results-and-to-Provide-an-Update-on-Clinical-Development-Programs-on-November-8-2022/default.aspx" rel="nofollow">View Source [SID1234622727]).
Conference Call Information
Reata’s management will host a conference call on November 8, 2022, at 8:30 am ET. The conference call will be accessible by dialing (844) 200-6205 (toll-free domestic) or (929) 526-1599 (international) using access code 756839. The webcast link is View Source
Third quarter 2022 financial results to be discussed during the call will be included in an earnings press release that will be available on the company’s website shortly before the call at View Source and will be available for 12 months after the call. The audio recording and webcast of the conference call will be accessible for at least 90 days after the event at View Source.